Introduction c-Jun NH 2 -terminal protein kinase (JNK) is a member of the mitogen-activated protein kinase (MAPK) superfamily, which also includes the extracellular signal-regulated kinase and p38 family of kinases (1) . JNK has two ubiquitously expressed isoforms, JNK1 and JNK2, and a tissuespecific isoform, JNK3, with different splicing forms (p54 and p46; refs. [2] [3] [4] . JNK is activated by sequential protein phosphorylation through a MAPK module [MAPK kinase kinase → MAPK kinase (or MKK) → MAPK] in response to a variety of extracellular stimuli (4, 5) . Two MAPK kinases, MKK4 and MKK7, and several MAPK kinase kinases are involved in JNK activation (4) . Once activated, JNK phosphorylates and regulates the activity of several transcription factors, such as c-Jun and c-Myc, as well as nontranscription factors, such as members of the Bcl-2 family proteins (4, 6) . Overwhelming evidence shows that JNK activity has a central role in regulating many cellular activities from cell cycle progression to apoptosis (2) (3) (4) .
JNK activity has been suggested to play a context-dependent role in tumorigenesis (3) . Several studies have linked JNK activity to tumor suppression. JNK1-null mice, which are deficient in JNK1 activity, exhibit enhanced sensitivity to skin tumorigenesis (7) . Loss-of-function mutations in the MKK4 gene are found in ∼5% of human tumors from a variety of tissues (8) . A recent study shows that MKK4 and MKK7 activity suppresses metastasis by inhibiting the ability of disseminated tumor cells to colonize the lung (9) . In contrast to studies that linked JNK activity to tumor suppression, other studies show protumorigenic roles for JNK activity, especially in malignant lymphocytes. For example, JNK1 activity is required in Bcr/Abl-mediated transformation of pre-B cells in vitro and in vivo (10) . B-lymphoma and multiple myeloma cells constitutively express high levels of the activated form of JNK and inhibition of JNK activity with an anthrapyrazolone inhibitor, SP600125, or JNKspecific small interfering RNA (siRNA), or JNK-specific antisense oligonucleotides leads to cell cycle arrest and apoptosis (11, 12) . Furthermore, it has been shown that oncogenic kinase, nucleophosmin-anaplastic lymphoma kinase, promotes cell cycle progression through activation of JNK/c-Jun signaling in anaplastic large-cell lymphoma (13) . The human T-cell lymphotropic virus oncoprotein Tax represses transforming growth factor-β1 signaling in human T cells via JNK/c-Jun hyperactivation, which may play a critical role in adult T-cell leukemia leukemogenesis (14) . JNK activity is also required for vascular endothelial growth factor expression in cutaneous T-cell lymphoma (15) .
T-cell acute lymphoblastic leukemia (T-ALL) is represented in only a small portion of hematologic malignancies but with very poor prognosis. The role of JNK activity in the oncogenic growth of T-ALL cells remains largely unknown. Here, we report that basal JNK activity, especially JNK1 activity, plays a pivotal role in the proliferation and survival of T-ALL cells via, at least partially, maintaining the protein levels of c-Myc and Bcl-2. These findings suggest that targeting JNK, especially JNK1 isoform, may have some important therapeutic implications in the treatment of T-ALL. Further exploration revealed that JNK protein and basal JNK activity in T-ALL cells showed aberrant subcellular localization, but no hyperactivation of JNK was observed. Thus, our work suggests that there might be novel mechanism(s) other than hyperactivation underlying the protumorigenic role of JNK activity.
Materials and Methods
Reagents JNK inhibitors SP600125 and AS601245 were purchased from Sigma and dissolved in DMSO. Whenever these inhibitors were used, DMSO was supplemented to keep concentrations of DMSO (<0.1%) equal in all the wells. Antibodies against phospho-JNK, total JNK, JNK2, MKK7, phosphop38, and phospho-extracellular signal-regulated kinase were from Cell Signaling Technology. Annexin V kit and antibodies against actin, JNK1, p38, phospho-c-Jun, c-Jun, c-Myc, Bcl-2, histone H1, and IκBα were from Santa Cruz Biotechnology. Antibodies against Bax, Bcl-XL, and Bim were from eBioscience. Antibody against human Fas (CH11) was obtained from BD Bioscience. Lipofectamine 2000 and neomycin were from Invitrogen.
Cells and Mice
The human T-ALL cell lines, CEM, HPB-ALL, HSB2, Jurkat, Molt3, and Molt4, as well as two human B-lymphoma cell lines, Daudi and Raji, were gifts from Dr. Ben Chen (Division of Hematology and Oncology, Department of Internal Medicine and Karmanos Cancer Institute, Wayne State University School of Medicine) and were grown in RPMI 1640 containing 10% fetal bovine serum, 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin. These cells were obtained and characterized in 1995 according to antigen/receptors expression. After that, the cells were frozen with multiple stocks until use in this work. For each cell line used in this work, cell stock was made in 5 to 7 days after resuscitation. The continuous passage time was always kept within 1 to 2 months. Human peripheral blood mononuclear cells (PBMC) were isolated from the heparinized peripheral blood of healthy volunteers by density gradient centrifugations. C57BL/6 mice ages 4 to 6 weeks were purchased from the Institute of Experimental Animals, Academy of Chinese Medical Sciences. Normal T lymphocytes were isolated from human PBMCs or splenic cells of C57BL/6 mice with Pan T-cell isolation kits (Miltenyi Biotech) according to the manufacturer's protocols.
Growth Assay and Soft-Agar Assay The growth of T-ALL cells was measured by the MTT incorporation assay. After the cells were cultured in 96-well plates for 68 h, 10 μL MTT (5 mg/mL) was added to each well. After 4 h, 100 μL of 10% SDS-10 mmol/L HCl were added to each well to dissolve the blue crystals of formazan. The samples were then measured at A 570 nm using an ELISA reader (Dynatech Laboratories). Soft-agar cloning assay was done as described previously (16) . The cells were seeded into 6-well plates with a density of 5 × 10 3 per well. On day 10, MTT incorporation was included to make the colonies visible. Each assay was repeated for three times.
Immunoblotting Analysis and Flow Cytometry The cells were treated under various conditions as indicated in the figure legends and were subjected to immunoblotting analysis or cell cycle assay as described previously (17) . To determine the extent of apoptosis, the cells were stained with FITC-conjugated Annexin V and propidium iodide using the Annexin V kit according to the manufacturer's protocol. Flow cytometry was carried out on a Becton Dickinson FACSCalibur machine (BD Biosciences).
Transfection of Plasmid and siRNAs into T-ALL Cells pcDNA3.1 MKK7-JNK1 was constructed according to a previous report (18) and verified by DNA sequencing. MKK7-JNK1 stable transfectants and mock control were generated by Lipofectamine 2000-mediated transfection of Jurkat cells with pcDNA3.1 MKK7-JNK1 and pcDNA3.1, respectively, and selected against neomycin (800 μg/mL). siRNAs that target human JNK1 and JNK2 mRNAs were designed based on nucleotides 1,013 to 1,031 (JNK1) and 461 to 479 (JNK2) relative to the translation start sites, respectively, and purchased from Dharmacon. Cells were transfected with siRNAs using Amaxa nucleofection kits according to the manufacturer's protocols.
Nuclear Cytoplasmic Fractionation Cells were collected in 50 mmol/L glycerophosphate (pH 7. Immunofluorescence Cells were dispersed on slides by cytospin, washed twice in PBS, fixed with 4% (w/v) paraformaldehyde in PBS for 10 min at room temperature, permeabilized with 0.5% Triton X-100 in PBS for 15 min, and then treated with 0.1 mol/L glycine in PBS for 15 min. The nonspecific sites were blocked by incubation with 1% bovine serum albumin in PBS for 30 min at room temperature. Cells were then rinsed in PBS containing 0.05% Tween 20 for 5 min and incubated with mouse monoclonal antibody against human JNK1 diluted in blocking buffer for 1 h at room temperature or overnight at 4°C. After being washed for three times in PBS containing 0.05% Tween 20, the cells were incubated with FITC-conjugated goat anti-mouse IgG for 45 min at room temperature. The cells were washed again as stated above, incubated with 1 μg/mL 4′,6-diamidine-2-phenylindole, and then observed under a laser scanning confocal microscopy (RADIANCE 2100; Bio-Rad).
Results

JNK Inhibitors SP600125 and AS601245 Induce a Dose-Dependent Reduction in the Growth of T-ALL Cells
It has been reported that JNK activity contributes to the oncogenic growth of various malignant lymphocytes such as B-lymphoma cells. To investigate whether JNK activity plays a similar role in T-ALL cells, two human T-ALL cell lines, HPB-ALL and Jurkat, as well as two human Blymphoma cell lines, Daudi and Raji, were treated with varying concentrations of JNK selective inhibitor SP600125 (19) . A dose-dependent reduction in the growth of human B-lymphoma cells, Daudi and Raji, was observed ( Fig. 1A ) as reported earlier (11) . Under the same conditions, SP600125 showed more significant inhibitory effect on the growth of HPB-ALL and Jurkat cells (Fig. 1A) . Consistently, soft-agar assay revealed that SP600125 suppressed the colony-forming ability of HPB-ALL and Jurkat cells more significantly than Daudi and Raji cells in a dose-dependent manner (Fig. 1B) . Besides HPB-ALL and Jurkat cells, SP600125 also suppressed the growth of other T-ALL cells, CEM, HSB2, Molt3, and Molt4 (Fig. 1C) . Furthermore, another JNK inhibitor, AS601245 (20, 21) , significantly suppressed the growth of T-ALL cells at the concentration of 10 μmol/L (Fig. 1D) . Because SP600125 and AS601245 inhibited the phosphorylation of c-Jun, but not extracellular signal-regulated kinase or p38 MAPK ( Supplementary  Fig. S1 ), at the concentration of 10 μmol/L they significantly suppressed the growth, the JNK inhibitors were efficient to inhibit JNK activity and showed selectivity against closely related kinases in T-ALL cells.
JNK Inhibitors Induce Cell Cycle Arrest and Apoptosis and Increased Sensitivity to Fas-Mediated Apoptosis in T-ALL Cells
Previous studies have revealed that the decreased growth of various tumor cells induced by inhibition of JNK activity was due to cell cycle arrest and/or apoptosis. Hence, we determined whether JNK inhibitors suppressed the growth of T-ALL cells via the same mechanism. Cell cycle assay revealed that HPB-ALL and Jurkat cells underwent G 2 -M arrest in the presence of either SP600125 or AS601245 ( Fig. 2A) . Furthermore, HPB-ALL and Jurkat cells showed a significant increase in sub-G 1 population, an indicator of apoptotic cells, with the treatment of JNK inhibitors ( Fig. 2A) . These data suggest that JNK inhibitors suppress the growth of T-ALL cells via cell cycle arrest and apoptosis.
Impairment of Fas-mediated apoptosis has been suggested to contribute to tumorigenesis (22) . Despite that JNK plays a proapoptotic role in response to various death stimuli, JNK activation is not required for Fas-mediated apoptosis (23, 24) . By contrast, it is reported that inhibition of JNK activity sensitizes some tumor cells to Fas-induced apoptosis (25) . Therefore, it is of importance to investigate whether it is the case in T-ALL cells. Apoptosis assay revealed that treatment of Jurkat cells with 50 ng/mL antiFas antibody (CH11) alone for 2 h induced up to ∼25% apoptosis (Fig. 2B) . Pretreatment of Jurkat cells with 10 μmol/L SP600125 for 12 h resulted in ∼12% apoptosis, whereas the basal level of apoptosis under the same condition was ∼4% (Fig. 2B ). These data confirm that inhibition of JNK activity induces apoptosis in T-ALL cells. Combination of SP600125 pretreatment and CH11 incubation led to ∼56% apoptosis, a percentage much higher than the sum of 25% and 12% (Fig. 2B) . Similar effects were also seen in CEM and Molt4 cells (Fig. 2B) , suggesting that JNK activity acts to antagonize Fas-mediated apoptosis in T-ALL cells.
Weak
If JNK activity indeed contributes to the oncogenic growth of T-ALL cells, selective activation of JNK in T-ALL cells should lead to accelerated cell cycle progression and resistance to Fas-mediated apoptosis. To test this scenario, Jurkat cells were stably transfected with a mammalian expression vector encoding MKK7-JNK1, because it has been shown that MKK7-JNK1 fusion protein linked via a short peptide can express profound JNK activity in the absence of any stimulus (18) . Immunoblotting analysis revealed weak expression of MKK7-JNK1 fusion protein in the two individual stable transfectants tested, Jurkat-y1 and Jurkat-y2 (Fig. 3A) . As expected, Jurkat-y1 and Jurkat-y2 underwent faster growth, exhibited less G 0 -G 1 cells, and were resistant to Fas-mediated apoptosis compared with mock control (Fig. 3B-D) . These data further suggest that JNK activity contributes to the oncogenic growth of T-ALL cells.
Protein Levels of c-Myc and Bcl-2 Are Regulated by JNK Activity in T-ALL Cells
Several studies have shown that dysregulated expression of the oncoprotein c-Myc is critical for the development of T-ALL (26, 27) , whereas the protein level of Bcl-2 determines the sensitivity to Fas-mediated apoptosis in various types of cells (28, 29) . JNK activity has been shown to regulate the protein levels of c-Myc and Bcl-2 family members in certain cell context (3, 10, 11, 30) . Therefore, it is of great importance to investigate whether levels of c-Myc and Bcl-2 family members in T-ALL cells are affected by variation of JNK activity. Immunoblotting analysis revealed that treatment of HPB-ALL and Jurkat cells with 10 μmol/L SP600125 for 12 to 24 h led to a significant reduction in Bcl-2 and cMyc protein levels (Fig. 4A) . Under the same conditions, SP600125 showed much weaker effect on the protein levels of Bax, Bcl-XL, and Bim (Fig. 4A , note that Bim was undetectable in HPB-ALL cells). Reduction in the protein levels of Bcl-2 and c-Myc was also observed in the presence of 10 μmol/L AS601245 (Fig. 4B) . By contrast, Bcl-2 and cMyc levels were increased in Jurkat-y1 and Jurkat-y2 cells compared with mock control (Fig. 4C) , which was reversed by 10 μmol/L SP600125 and AS601245 (Fig. 4D) . The concentration (10 μmol/L) at which JNK inhibitors led to reduced protein levels of Bcl-2 and c-Myc is associated with significant inhibition of growth (Fig. 1) , significant inhibition of JNK activity, and selectivity against closely related kinases in T-ALL cells (Supplementary Fig. S1 ). Taken together, these data suggest that the protein levels of c-Myc and Bcl-2 are regulated by JNK activity in T-ALL cells.
siRNA against JNK1, but not JNK2, Exhibits Similar Effects to JNK Inhibitors
In mammals, there are three JNK genes, Jnk1, Jnk2, and Jnk3, with different splicing forms (p54 and p46; refs. 2-4). JNK1 and JNK2 are ubiquitously expressed, whereas expression of JNK3 is restricted to brain, heart, and testis (2-4). To test which isoform plays a major role in the protumorigenic effects of JNK activity in T-ALL cells, knockdown of individual kinases, JNK1 and JNK2, was pursued. By using different antibodies that specifically recognize either JNK1 or JNK2, we were able to show successful silencing of JNK1 and JNK2 specifically and independently in CEM cells (Fig. 5A) . Reduction in the protein levels of JNK1 or JNK2 resulted in significant less p46 JNK activity and p54 JNK activity, respectively (Fig. 5A ). JNK1 siRNA, but not JNK2 siRNA, led to reduced protein levels of Bcl-2 and c-Myc (Fig. 5A) . Consistently, there was significant growth inhibition in CEM cells transfected with JNK1 siRNA but not JNK2 siRNA (Fig. 5B) . The growth inhibition was accompanied by an increase in G 0 -G 1 phase and slightly more basal apoptosis (Fig. 5C and D) . Knockdown of JNK1, but not JNK2, also augmented Fas-mediated apoptosis (Fig. 5D) . Similar growth-inhibitory and proapoptotic effects of JNK1 siRNA, but not JNK2 siRNA, were also observed in Jurkat cells (Supplementary Fig. S2 ). Thus, our data suggest that JNK1, but not JNK2, is the major player in the protumorigenic role of JNK activity in T-ALL cells.
JNK Protein and Basal JNK Activity in T-ALL Cells Show Aberrant Subcellular Localization, but No Hyperactivation of JNK Is Observed
Hyperactivation of JNK has been found in various malignant lymphocytes and inhibition of JNK activity leads to cell cycle arrest and apoptosis. Now that JNK activity also contributes to the oncogenic growth of T-ALL cells, it is reasonable to suppose that T-ALL cells exhibit higher levels of JNK activity than primary T cells. To test this scenario, HPB-ALL and Jurkat cells were serum-starved for 24 h, and the cells were stimulated with 20% fetal bovine serum for 15 min or left untreated. The levels of JNK phosphorylation were compared with those in human PBMC T cells. Immunoblotting analysis revealed that both HPB-ALL and Jurkat cells exhibited detectable levels of basal JNK phosphorylation even after serum starvation, and fetal bovine serum treatment for 15 min significantly activated JNK in these cells (Fig. 6A) , consistent with the finding that JNK activity contributes to the oncogenic growth of T-ALL cells. However, the levels of JNK phosphorylation in both serum-starved and fetal bovine serum-stimulated HPB-ALL and Jurkat cells were surprisingly lower than in human PBMC T cells (Fig. 6A) . Furthermore, the basal JNK activity in all the six T-ALL cell lines used in this work was lower than in murine splenic T cells and murine thymocytes despite that all the T-ALL cells expressed detectable levels of the activated form of JNK ( Fig. 6B ; data not shown). These data are contradictory to our hypothesis and suggest that JNK activity contributes to the oncogenic growth of T-ALL cells independent of hyperactivation.
JNK phosphorylates a broad spectrum of substrates distributed throughout different subcellular compartments (31) . The balance among these site-specific components of JNK signaling determines the biological outcomes (31) . Because JNK activity contributes to the oncogenic growth of T-ALL cells via maintaining the protein levels of c-Myc and Bcl-2, it most likely does so in the nucleus by regulating transcription. Therefore, the basal JNK activity in the nucleus is a more important factor. To compare the subcellular distribution of basal JNK activity between primary T cells and T-ALL cells, nuclear cytoplasmic fractionation was applied to human PBMC T cells, Jurkat cells, and Molt4 cells. It is found that the basal JNK activity in primary T cells exhibited exclusive cytoplasm localization, whereas T-ALL cells showed aberrant nuclear accumulation of basal JNK activity (Fig. 6C) . The discrepancy might result from the different subcellular distribution of JNK protein in primary T cells and T-ALL cells because JNK protein in primary T cells was cytoplasmic, whereas JNK protein in T-ALL cells was both nuclear and cytoplasmic (Fig. 6C) . Immunofluorescences confirmed the aberrant subcellular localization of JNK protein in all the six T-ALL cell lines used in this work, in contrast to the exclusive cytoplasm localization of JNK protein in both murine splenic T cells and human PBMC T cells ( Fig. 6D; Supplementary Fig. S3 ). Taken together, our data suggest that JNK activity contributes to the oncogenic growth of T-ALL cells via aberrant subcellular localization but not hyperactivation.
Discussion
Hyperactivation of JNK has been found in various malignant lymphocytes. As for T-ALL cells, however, it is apparently not the case. In this work, T-ALL cells were found to express detectable levels of basal JNK phosphorylation. However, the basal JNK activity in all the six T-ALL cell lines tested was surprisingly lower than in primary T cells. An intriguing fact is that the weak basal JNK activity was essential for survival and proliferation of T-ALL cells. Thus, hyperactivation is not a prerequisite for JNK activity to exhibit a protumorigenic role. There might be novel mechanism(s) other than hyperactivation underlying the protumorigenic role of JNK activity.
Our data revealed that the basal JNK activity in primary T cells exhibited exclusive cytoplasm localization, whereas T-ALL cells showed aberrant nuclear accumulation of basal JNK activity. The discrepancy might result from the different subcellular distribution of JNK protein in primary T cells and T-ALL cells because JNK protein in primary T cells was cytoplasmic, whereas JNK protein in T-ALL cells was both cytoplasmic and nuclear. Although some published data revealed the importance of JNK nuclear localization for the induction of cell death in certain cell context (32, 33) , accumulation of basal JNK activity in the nucleus was seen in tumor cells (34, 35) . Our preliminary data ( Supplementary  Fig. S4 ) also showed more nuclear entry of JNK protein in malignant B cells compared with its normal counterparts. Meanwhile, it has been established that JNK plays a protu- Figure 5 . JNK1 siRNA, but not JNK2 siRNA, shows growth-inhibitory and proapoptotic effects in CEM cells. CEM cells were transfected with JNK1 siRNA or JNK2 siRNA or the nontargeting negative control siRNA and cultured for 48 h. A, cell lysates were prepared and phosphorylation of JNK and expression of JNK1, JNK2, actin, Bcl-2, and c-Myc were determined by immunoblotting. Ctrl, control; P-JNK, phospho-JNK. B, growth of these cells was measured as described in Fig. 1A . C, cell cycle assay was done by propidium iodide staining. The percentages of G 0 -G 1 cells are shown as mean ± SD (n = 3). D, cells were treated with 150 ng/mL CH11 for 2 h or left untreated. The cells were subjected to apoptosis assay. Right, mean ± SD (n = 3); left, representative of three independent experiments. morigenic role in malignant B cells. These observations suggest a protumorigenic role for basal nuclear JNK activity in tumor cells. T-ALL cells might make use of JNK aberrant subcellular localization to maintain enough JNK activity in the nucleus for oncogenic growth under the condition that there is no hyperactivation of JNK. It is of importance to elucidate whether translocation of JNK to the nucleus plays any role in cell cycle progression and resistance to apoptosis. However, little is known about the mechanism of JNK localization (36). It is not possible yet to specifically block the translocation of JNK to the nucleus to show whether the aberrant subcellular localization of JNK protein and basal JNK activity in T-ALL cells contribute to the protumorigenic role of JNK. Further studies are required to clarify these issues.
Nevertheless, T-ALL cells retained some JNK activity, and our data show that JNK activity in a low range contributed to the survival and proliferation of T-ALL cells in a dosedependent manner. These findings suggest that targeting JNK may have some important therapeutic implications in the treatment of T-ALL. For this purpose, an important point to consider is the role of JNK isoforms and/or their ratio. Different JNK isoforms possess structural and biochemical similarities. All of them contribute to JNK activity and have many overlapping functions (2-4). However, JNK1 and JNK2 have recently been shown to exhibit some differences in their substrate specificities and gene targets (3, 4, 37) . Our data suggest that, in T-ALL cells, phosphorylation of p46 JNK mainly comes from JNK1, whereas phosphorylation of p54 JNK mainly comes from JNK2. JNK1 siRNA, but not JNK2 siRNA, showed growth-inhibitory and proapoptotic effects in T-ALL cells, although the effects of JNK1 siRNA were weak compared with JNK inhibitors because of partial knockdown. These data further support a protumorigenic role for JNK activity in T-ALL cells and suggest that targeting JNK should focus on JNK1, but not JNK2, for the treatment of T-ALL. 
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